Plus Financial Statements From 2010 to 2025

Stocks . USA . 
Stock . Plus Therapeutics
PSTV Stock  USD 0.56  0.03  5.08%   
Plus Therapeutics financial statements provide useful quarterly and yearly information to potential Plus Therapeutics investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Plus Therapeutics financial statements helps investors assess Plus Therapeutics' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Plus Therapeutics' valuation are summarized below:
Gross Profit
-5.5 M
Profit Margin
(2.25)
Market Capitalization
3.5 M
Enterprise Value Revenue
18.192
Revenue
5.7 M
There are over one hundred nineteen available trending fundamental ratios for Plus Therapeutics, which can be analyzed over time and compared to other ratios. All traders should should check out Plus Therapeutics' recent fundamental trends against the trends from 2010 to 2025 to make sure the company is sustainable. Market Cap is likely to climb to about 9.9 M in 2025, whereas Enterprise Value is likely to drop slightly above 1.2 M in 2025.

Plus Therapeutics Total Revenue

5.64 Million

Check Plus Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Plus Therapeutics' main balance sheet or income statement drivers, such as Interest Expense of 337.7 K, Selling General Administrative of 10.2 M or Selling And Marketing Expenses of 637 K, as well as many indicators such as Price To Sales Ratio of 1.22, Dividend Yield of 0.0022 or Days Sales Outstanding of 46.47. Plus financial statements analysis is a perfect complement when working with Plus Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Plus Therapeutics Correlation against competitors.
For more information on how to buy Plus Stock please use our How to Invest in Plus Therapeutics guide.

Plus Therapeutics Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets9.7 M10.2 M26.1 M
Slightly volatile
Short and Long Term Debt Total4.6 M4.8 M13 M
Slightly volatile
Cash14.2 M9.8 M14.3 M
Pretty Stable
Cash And Short Term Investments14.1 M7.7 M14.2 M
Pretty Stable
Common Stock Shares Outstanding3.8 M3.6 M844.5 K
Slightly volatile
Liabilities And Stockholders Equity9.7 M10.2 M26.1 M
Slightly volatile
Non Current Liabilities Total1.7 M1.8 M10 M
Slightly volatile
Total Liabilities25.2 M14.6 M22.5 M
Slightly volatile
Total Current Assets17.1 M8.9 M18.4 M
Slightly volatile
Total Current Liabilities10.5 M12.3 M11.8 M
Very volatile
Property Plant And Equipment Net947.3 K997.2 K1.9 M
Slightly volatile
Non Current Assets Total1.3 M1.4 M8.4 M
Slightly volatile
Non Currrent Assets Other35 K36.8 K1.8 M
Pretty Stable
Net Receivables6 K6.3 K1 M
Slightly volatile
Other Current Assets1.2 M1.5 M1.3 M
Slightly volatile
Other Stockholder Equity286.3 M551 M371.8 M
Slightly volatile
Short Term Debt4.6 M4.7 M5.9 M
Very volatile
Common Stock5.5 K5.8 K42.2 K
Slightly volatile
Current Deferred Revenue1.2 M1.3 M277.3 M
Slightly volatile
Common Stock Total Equity7.6 K8.1 K40.4 K
Slightly volatile
Property Plant And Equipment Gross2.1 M3.3 M2.4 M
Very volatile
Intangible Assets35.9 K37.8 K4.1 M
Slightly volatile
Good Will318.1 K334.8 K2.2 M
Slightly volatile
Capital Surpluse424.5 M502 M389.6 M
Slightly volatile
Property Plant Equipment2 M1.8 M1.7 M
Slightly volatile
Other Assets10.3 K10.8 K1.9 M
Slightly volatile
Other Liabilities1.4 M1.9 M1.1 M
Slightly volatile
Net Invested Capital2.2 M2.4 M18.2 M
Slightly volatile
Capital Stock5.5 K5.8 K13.3 K
Pretty Stable

Plus Therapeutics Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Interest Expense337.7 K355.5 K1.9 M
Slightly volatile
Selling General Administrative10.2 M9.8 M9.5 M
Pretty Stable
Selling And Marketing Expenses637 K670.5 K3.3 M
Slightly volatile
Other Operating Expenses27.8 M21 M24.9 M
Slightly volatile
Research Development11.7 M11.1 M10.5 M
Pretty Stable
Total Operating Expenses9.3 M9.8 M21.1 M
Slightly volatile
Cost Of Revenue11.7 M11.1 M4 M
Slightly volatile
Depreciation And Amortization968.9 K565.2 K980.1 K
Pretty Stable
Interest Income367.6 K360 K1.4 M
Slightly volatile
Reconciled Depreciation806.7 K565.2 K1.5 M
Slightly volatile

Plus Therapeutics Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow13.9 M20.8 M17.8 M
Slightly volatile
End Period Cash Flow14.5 M9.8 M14.5 M
Pretty Stable
Depreciation963 K565.2 K968.8 K
Pretty Stable
Stock Based Compensation486.5 K512.1 K72.4 M
Slightly volatile
Issuance Of Capital Stock9.1 M5 M9.5 M
Very volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio1.221.2914.1204
Pretty Stable
Dividend Yield0.00220.00250.0028
Slightly volatile
Days Sales Outstanding46.4763.9762.4581
Pretty Stable
Stock Based Compensation To Revenue0.130.115813.1088
Slightly volatile
Capex To Depreciation0.280.290.9119
Slightly volatile
Sales General And Administrative To Revenue1.491.578.0951
Slightly volatile
Research And Ddevelopement To Revenue2.991.787.423
Slightly volatile
Capex To Revenue0.02780.02930.4601
Slightly volatile
Cash Per Share2.983.1313.1 K
Slightly volatile
Income Quality1.131.110.9281
Very volatile
Intangibles To Total Assets0.03970.04180.1428
Slightly volatile
Current Ratio1.01.053.6968
Slightly volatile
Receivables Turnover5.615.918.6367
Very volatile
Capex Per Share0.05570.0586510
Slightly volatile
Revenue Per Share1.711.86 K
Slightly volatile
Interest Debt Per Share1.591.6812.6 K
Slightly volatile
Debt To Assets0.250.330.4406
Slightly volatile
Ebt Per Ebit1.091.15123
Slightly volatile
Long Term Debt To Capitalization0.350.330.4887
Slightly volatile
Total Debt To Capitalization1.391.330.8395
Slightly volatile
Quick Ratio1.01.053.4667
Slightly volatile
Net Income Per E B T0.970.921.2496
Pretty Stable
Cash Ratio0.870.921.6348
Slightly volatile
Days Of Sales Outstanding46.4763.9762.4581
Pretty Stable
Free Cash Flow Operating Cash Flow Ratio1.291.161.1082
Pretty Stable
Fixed Asset Turnover3.043.994.0747
Slightly volatile
Debt Ratio0.250.330.4406
Slightly volatile
Price Sales Ratio1.221.2914.1204
Pretty Stable
Asset Turnover0.260.50.2368
Very volatile

Plus Therapeutics Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap9.9 M6.3 M8.6 M
Pretty Stable
Enterprise Value1.2 M1.3 M5.6 M
Slightly volatile

Plus Fundamental Market Drivers

Cash And Short Term Investments8.6 M

Plus Upcoming Events

22nd of February 2024
Upcoming Quarterly Report
View
18th of April 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
22nd of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Plus Therapeutics Financial Statements

Plus Therapeutics investors use historical fundamental indicators, such as Plus Therapeutics' revenue or net income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Plus Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue1.3 M1.2 M
Total Revenue4.4 M5.6 M
Cost Of Revenue11.1 M11.7 M
Stock Based Compensation To Revenue 0.12  0.13 
Sales General And Administrative To Revenue 1.57  1.49 
Research And Ddevelopement To Revenue 1.78  2.99 
Capex To Revenue 0.03  0.03 
Revenue Per Share 1.80  1.71 
Ebit Per Revenue(3.12)(3.27)

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Plus Stock Analysis

When running Plus Therapeutics' price analysis, check to measure Plus Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Plus Therapeutics is operating at the current time. Most of Plus Therapeutics' value examination focuses on studying past and present price action to predict the probability of Plus Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Plus Therapeutics' price. Additionally, you may evaluate how the addition of Plus Therapeutics to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY